DSP's Boston acquisition in line with Japanese pharma's shift to oncology

Dainippon Sumitomo Pharma (DSP) liked the product so much they bought the company. But while an initial March 2011 option agreement with Boston Biomedical for an oncology candidate may have led to DSP acquiring the private US firm, the deal is also very much in line with similar moves by larger pharma companies in Japan.